William C. Hahn, MD, PhD, deputy chief scientific officer at Dana-Farber Cancer Institute (DFCI) in Boston, MA, began his 1-year term as president of the American Society for Clinical Investigation (ASCI) in April. With more than 2,800 elected members representing all specialties, the ASCI is dedicated to advancing research to improve treatment of human diseases. The organization also publishes the peer-reviewed Journal of Clinical Investigation.
Hahn, who is also chief of molecular and cellular oncology at DFCI and director of its Center for Cancer Genome Discovery, studies the genetic interactions that lead to malignant transformation of cells. His laboratory has developed experimental models for the study of normal and malignant epithelial cell biology and helped develop genome-scale tools that permit the manipulation of genes in a comprehensive manner. Using these tools, he is identifying and validating new targets for translational cancer research. [Photo courtesy Aaron Washington.]
Robert A. Bradway, MBA, assumed the role of chief executive officer of Amgen (Thousand Oaks, CA) in May, replacing Kevin W. Sharer, who will retire at the end of the year. Amgen identifies, isolates, produces, and uses human proteins as therapeutic agents in the treatment of various cancers and other serious illnesses. The company boasts 17,000 employees at facilities in dozens of countries. Its 10 approved drugs generated $15.3 billion in sales in 2011.
Bradway joined Amgen in 2006 as a vice president in operations and worked his way up to chief financial officer in 2007 and then president and chief operating officer in 2010. Before joining Amgen, he spent 19 years at Morgan Stanley.
For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.